



FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO 1038-1129 MIS:ac	SERIAL NO. 09/786,235
	APPLICANT Diane M. Gajewczyk et al	
	FILING DATE September 3, 1999	GROUP

**U.S. PATENT DOCUMENTS**


*INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUBCL.	FILING DATE
AS		6,004,557	Dec. 1999	Edwards et al.			
		6,013,258	Jan. 2000	Urban et al.			
		5,744,133	April 1998	Lathe et al.			

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCL.	TRANSLATION	
AS		WO 96/00583	Jan. 11/96				YES	NO
		WO 92/16636	Oct. 1/92					
		WO 97/05164	Feb. 13/97					
		WO 99/18995	Apr. 22/99					
		WO 93/24640	Dec. 9/93					

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

AS	**	1. Pisani P. et al., Estimated of the worldwide mortality from eighteen major cancers in 1985. Int. J. Cancer 1993 : 55 : 891-903
	**	2. Piver M.S., Handbood of gynecologic oncology. Boston: Little, Brown, 1996.
	**	3. Kurman R.J. et al., Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute Workshop, IAMA 1994-271 : 1866-9.
	**	4. Bosch FX, et al., Prevalence of hman papillomavirus in cervical cancer a worlwide perspective. J. National Cancer Institute. 1995:87:796-802.
	**	5. Pecoraso G. et al., Differential effects of human papillomavires type 6, 16 and 18 DNAs ... USA, 1989 : 86, pp. 563-567.
	**	6. Shamanin C.G., et al., Specific types of human papillomavirus found in bening preliférations and carcinomas of the skin in immunosuppressed patients. Cancer Res. 1994:54, pp. 4610-3.
	**	7. Hilders C.G., et al., Association between HLA-expression and infiltration of immune cells in cervical carcinoma. Laboratories Investigation. 1993: 69, pp.651-619.
	**	8. Munger K., et al., Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products. Cancer Surv. 1992:12, pp. 197-217.
	**	9. Dyson N., et al., The human papilloma virus-16 E7 oncoproteins with tumour .....Science : 1989:243, pp.934-937.
	**	10. Munger K., et al., Virol 1989 : 63, pp. 4417-4421.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO 1038-1129 MIS:ac	SERIAL NO. 09/786,235
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  		APPLICANT Diane M. Gajewczyk et al	
		FILING DATE September 3, 1999	GROUP

AS ↓		11. Crook t., et al., Journal 1989 : 8, pp. 513-519	
		12. Rensing M.E., et al., J. Immunol. 1995:154, pp. 5934-5943, XP002915422	
	**	13. Kast W.M., et al., J., Immunol. 1994:152, pp. 3904-3912.	
		14. Feltkamp M.C., et al., Immunol. 1993:23, pp. 2242-2249.	
	**	15. Alexander M., et al., J. Obstet. Gynecol 1996:175, pp. 1586-1593.	
	**	16. Steller M.A., et al., Human Papillomavirus immuology and vaccine prospects.J. Natl. Cancer Inst. Monogr. 1996:21, pp. 145-148.	
	**	17. Schiller J.T., et al., Papillomavirus vaccines: Current status and future prospects. Adv. Dermatol 1996:11, ppl355-80; discussion: 355-80; discussstion:381.	
	**	18. Kimbauer R., et al., J. Virol 1993:67, pp. 6929-6936.	
		19. Borysiewicz L.K. et al., Lancet 1996:347, pp. 1523-1527.	
	**	20. Irvine K.R., et al., J. Immunol. 1995:154, pp. 4651-4657.	
		<del>21. WO 93/24640</del> <i>duplicate</i>	
		22. Tang et al., Nature 1992, 356: pp. 152-154.	
		23. Furth et al., Analytical Biochemistry, 1992, 205, pp. 365-368.	
		24. Munger K. et al., The EMBO Journal , 1989, vol. 8: 13, pp. 4099-4105. XP000611714.	
		25. Sundaram P., et al., Vaccine 1998 : vol. 16. : 6, pp. 613-623. XPO002131646.	
	EXAMINER:	DATE CONSIDERED: 8/11/05	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if in conformance and not considered. Include copy of this form with next communication with applicant.

\*\* Will follow shortly